43 Biotechnology & Immunology New Dengue NS1 Antibodies for Lateral Flow Applications
Dengue Virus is endemic in tropical countries worldwide. It causes an insect-borne (mosquitoes) infection that manifests as Dengue Fever. However, it can progress to more serious conditions including hemorrhagic fever. There are 4 serotypes of the virus and all are capable of causing disease. A non-structural glycoprotein (NS1) is produced during acute infection and can be found at high levels in patient serum.
ViroStat has released several new monoclonal antibodies to the NS1 of Dengue virus. These antibodies recognise the NS1 protein of all 4 Dengue serotypes and have recently been validated for lateral flow immunoassay rapid detection methods.
42226pr@reply-direct.com
New LAG-3 Agonist Antibody Product Candidate Announced
Prima BioMed Ltd announces that it has developed a new early stage product candidate, a humanised IgG4 monoclonal antibody to be known as IMP761. This antibody, developed at the Company’s laboratory in Châtenay-Malabry, south of Paris, is believed to be the first agonist antibody of LAG-3.
The IMP761 agonist antibody is an exciting new addition to the Prima pipeline of product candidates. It is mechanistically distinct from any of the known LAG-3 antibodies. Prima continues to lead the way in researching and developing novel LAG-3 targeting technologies.
Dr Frédéric Triebel said: “Even though IMP761 is an early stage product, we are very excited to have developed what we believe is the first ever agonist of LAG-3. Until now, therapeutic antibodies with agonistic properties have not been described for any of the three major immune checkpoints, CTLA-4, PD-1 or LAG-3. IMP761 promises the first opportunity for fine tuning of the immune response to an immune checkpoint target. This singular biological activity of IMP761 could benefit sufferers of certain autoimmune diseases by temporarily switching off activated LAG-3+ T cells that are damaging tissue or creating inflammatory responses.”
Prima CEO, Mr Marc Voigt commented: “Our ongoing research efforts in the Paris laboratory are further consolidating our leading position in the development of LAG-3 product candidates. With development of IMP761, Prima is harnessing even more of the therapeutic potential of the LAG-3 target. Our antagonist and agonist antibodies can respectively increase immune responses (for cancer indications) or decrease such responses (for auto-immune diseases), suggesting exciting options for novel immunotherapies. As IMP761 is early stage, in 2017 we will focus on pre-clinical development, including in vivo efficacy model studies, to better understand its potential applications.”
41441pr@reply-direct.com ADVERTORIAL How Freeze Drying Optimises the Processing & Viability of Collagen Bio-Scaffolds
Collagen is the main structural protein in the extracellular space in various connective tissues. It constitutes about 30% of the total human body protein being found in fi brous tissues such as tendons, ligaments, blood vessels and bone, providing structural support and strength.
Collagen bio-scaffolds are used to guide and encourage tissue regeneration in sponge, thin sheets or gel form and is used for both in-vivo and in-vitro processes.
Collagen has properties useful for tissue regeneration: pore structure, permeability and stability in-vivo. Structure and pore size is very important and can have a signifi cant effect on the growth of new tissue. When new tissue grows in the pores, the bio-scaffold degrades, leaving only healthy tissue. Two key processes affecting pore size in bio-scaffolds are:
Freeze drying:
This process not only increases shelf life of the material, but controls pore size, which is vital for the growth of new tissue. Collagen is extremely sensitive to the cooling rate, therefore, it is important to choose a suitable cooling rate as well as a container that has an appropriate heat transfer coeffi cient as this can have a signifi cant effect on properties of the fi nal product.
The addition of an annealing step and freeze drying a material twice can also be employed to obtain the desired structure.
Crosslinking:
A crosslink is a bond that links one polymer chain to another. Precaution must be taken during the crosslinking process as a micro collapse may be generated, which specifi cally happens in collagen-based products when they are impregnated with other solutes then lyophilised.
Choosing the correct crosslinking agent for your specifi c purpose is vital, and one should be made aware that some of the agent will likely remain in the fi nal freeze dried product.
Biopharma Group has undertaken numerous projects determining the effect of different freezing rates and the addition of an annealing step on the pore size of various collagen based products. In addition, we have developed cycles for customers, achieving collagen products with different pore sizes, and we look forward to future challenges in this fi eld.
41866pr@reply-direct.com 7469ad@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68
